La Jolla Pharmaceutical Company
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
La Jolla Pharmaceutical Company - overview
Established
1989
Location
Waltham, MA, US
Primary Industry
Pharmaceuticals
About
La Jolla Pharmaceutical Company is a biopharmaceutical firm focused on developing innovative therapeutics to address unmet medical needs in critical care and infectious diseases. La Jolla Pharmaceutical Company, headquartered in Waltham, US, specializes in biopharmaceuticals. Founded in 1989, the company has undergone a significant shift in business strategy. In July 2022, Innoviva, Inc.
agreed to acquire La Jolla at USD 5. 95 per share from Healthcare Royalty Partners. The company has raised a total of USD 125. 00 mn through its latest PIPE round, which was led by Healthcare Royalty Partners.
The CEO of the company is Larry Edwards. La Jolla Pharmaceutical Company develops innovative therapies, including GIAPREZA® for severe hypotension and XERAVA® and XACDURO® for serious bacterial infections. These products are designed to meet urgent healthcare needs and are marketed primarily to hospitals and healthcare providers across the US and European Union. In 2021, La Jolla Pharmaceutical Company reported a revenue of USD 75.
72 mn and an EBITDA of USD 23. 71 mn, reflecting its commercial activities in the pharmaceutical market. With the recent acquisition deal expected to close shortly after July 11, 2022, La Jolla Pharmaceutical Company aims to expand its product pipeline and enhance its market presence. The company is likely to invest in new therapeutic developments and explore geographical expansion to further penetrate critical care markets.
Primary Industry
Pharmaceuticals
Sub Industries
Biopharmaceuticals, Pharmaceutical Research & Development
Website
www.lajollapharmaceutical.com
Company Stage
Acquired
Total Amount Raised
Subscriber access only
La Jolla Pharmaceutical Company - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Trade Sale | Completed | La Jolla Pharmaceutical Company | - | ||||||||
| Add-on | Completed | Tetraphase Pharmaceuticals, Inc. | - | ||||||||
| PIPE | Completed | La Jolla Pharmaceutical Company | - |
Displaying 1 - 3 of 3
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.